Kaiser Permanente
Division of Research Spotlight
The Kaiser Permanente Division of Research conducts, publishes, and disseminates epidemiologic and health services research to improve the health and medical care of Kaiser Permanente members and society at large. We seek to understand the determinants of illness and well-being, and to improve the quality and cost-effectiveness of health care. Currently, DOR’s 550-plus staff is working on more than 350 epidemiological and health services research projects.
Adults with young children – and exposure to their colds – were less likely to have severe illness from COVID-19 than similar adults without children, a Kaiser Permanente study finds.
A new study led by Kaiser Permanente researchers provides reassurance about vaccinating infants whose mothers took biologic medications for an autoimmune disorder during pregnancy.
COVID-19 patients in Kaiser Permanente Northern California hospitals during the delta surge of 2021 were less likely to die in the hospital of COVID-19 if they were vaccinated, new research finds.
A Kaiser Permanente analysis of pregnant patients who tested positive for the coronavirus found more than double the risk of poor outcomes including preterm birth, venous thromboembolism (blood clot), and severe maternal morbidity, which includes conditions such as acute respiratory distress syndrome and sepsis.
An analysis of early data on the effectiveness of the Pfizer/BioNTech COVID-19 vaccine in children and teens found that a third shot, or booster, extended protection against emergency department and urgent care visits in 16- and 17-year-olds.
The Kaiser Permanente study found the risk difference was more pronounced in women, Asians and Pacific Islanders, and people under 40.
A study reviewing 16 years of patient data found nearly double the rate of dementia among people with HIV compared with those without HIV. The rate of dementia decreased over time for both groups but remained higher for those with HIV, reported research published in the journal AIDS.
Federal and Kaiser Permanente researchers combing the health records of 6.2 million patients found no serious health effects that could be linked to the 2 mRNA COVID-19 vaccines.
A large, detailed look by Kaiser Permanente researchers at patients taking HIV-prevention drug therapy finds strong adherence soon after patients get the prescription, but less consistent use thereafter, particularly among groups considered high priority for receiving the medication.
Division of Research investigator Ousseny Zerbo, PhD, describes his long journey from his childhood and education in Burkina Faso to becoming an epidemiologist in Northern California.
